SAT0502 EFFICACY AND SAFETY OF ADALIMUMAB IN JUVENILE IDIOPATHIC ARTHRITIS – 10 YEAR EXPERIENCE USING DATA OF THE BIKER REGISTRY
Authors: Gerd Horneff, Kisten Minden, Toni Hospach, Ivan Foeldvari, Peter Haas, Angelika Thon, Betina Rogalski, Gerd Ganser, Frank Weller-Heinemann, Andreas Urban, Markus Hufnagel, Prasad Oommen, Ariane Klein
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Since 2008, Adalimumab is approved for polyarticular juvenile idiopathic arthritis (JIA) and approval has been extended to other JIA categories and for uveitis. <h3>Objectives</h3> To evaluate efficacy and safety of Adalimumab in clinical practice in JIA patients in comparison to a biologic-naïve JIA cohort using the German Biologics registry (BiKeR). <h3>Methods</h3> Baseline demographics and disease activity parameters have been documented. Efficacy was determined using the JADAS10. Safety assessments were based on adverse events (AE) reports processed according to MedDRA. <h3>Results</h3> Until October 1, 2018, 951 JIA patients treated with Adalimumab were registered in BiKeR, representing 1519 patient-years (PY) of exposure. The total observation time (from date of first dose until last follow-up, censored, if another biologic was started) was calculated with 1709 PY. At baseline, the cohort treated with Adalimumab had experienced disease with a disease duration of 5.4+/-3.9 years (mean+/-SD). 849 patients (89.3%) were pretreated with methotrexate, 525 (54.2%) with Etanercept. Concomitantly, 584 (61.4%) received methotrexate, 529 (55.6%) NSAIDs and 255 (26.8%) systemic corticosteroids. In the control cohort, 1517 biologic naive JIA patients started methotrexate. Upon treatment, the median (IQR1-3) JADAS10 score decreased from 9.8 (4.7-15.5) at baseline to 3.9 (0.9-9.7) at the last follow-up. With respect to patients with ongoing treatment, approximately 43% achieved a JADAS defined minimal disease activity while 25% reached a JADAS defined remission at last follow-up. 904 AE have been observed during exposure or up to 90 days follow-up (58.4/100 exposure years (EY) [95% CI 54.7-62.3]). 66 qualified as serious AE (SAE) (4.3/100 EY [3.3-5.4]). These figures were compared to 1294 AE reported in the control cohort (34.8/year [32.9-36.8]) and 52 SAE (1.4/100 EY [1.1-1.8]). Adverse events of special interest were serious/medically important infection (n=33), opportunistic infection (n=6, all H. zoster), malignancy (n=2), anaphylaxis/hypersensitivities (n=3), thrombotic disorders (n=2), autoimmune diseases (n=91, including 12 cases with psoriasis and 53 reports of uveitis), bleeding (n=3), cytopenias (n=4), pregnancies (n=2). Macrophage activation syndrome, demyelination, cardiac or cerebral infarction, or death were not observed. However, 2 malignancies were reported in patients who had ever been exposed to Adalimumab before. Both events were judged as unrelated. A total of 449 patients (48.5%) discontinued Adalimumab, 188 (19.8%) due to lack of efficacy, 111 (11.7%) due to remission and 78 (8.2%) because of intolerance. <h3>Conclusion</h3> The current analysis adds to the established safety profile of Adalimumab and demonstrates that the rate of SAEs was comparable and consistent with the overall AE profile in paediatric patients. As expected, infections were the most frequent SAE. Uveitis, as well as psoriasis, are likely associated with JIA. Of notice, only one patient developed a chronic inflammatory bowel disease. No new safety signals specific to the paediatric population were identified in this large cohort of JIA patients. <h3>References</h3> [1] Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry. Scand J Rheumatol. 2018Nov9:1-10. <h3>Acknowledgement</h3> The authors acknowledge all patients, parents and ciontributors to the BIKER registry and Abbvie, Germany, for financial Support for parts of BIKER. <h3>Disclosure of Interests</h3> Gerd Horneff: None declared, Kisten Minden Grant/research support from: Pfizer, Abbvie, Toni Hospach Speakers bureau: Chugai, Roche, Novartis, Ivan Foeldvari Consultant for: Chugai, Novartis, Peter Haas Grant/research support from: Pfizer, Angelika Thon: None declared, Betina Rogalski &lt;: None declared, Gerd Ganser: None declared, Frank Weller-Heinemann: None declared, Andreas Urban: None declared, Markus Hufnagel: None declared, Prasad Oommen: None declared, Ariane Klein: None declared